Efficacy of a KChannel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis.

Abstract

INTRODUCTION/AIMS: Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP). We assessed the efficacy of a second-generation potassium channel agonist, XEN1101, to prevent and abort the low-Kinduced loss of force in mouse models of HypoPP. METHODS: An ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving contractile force and for enhancing recovery of force in the setting of a low-Kchallenge for HypoPP mice carrying the sodium channel Na1.4-R669H or the calcium channel Ca1.1-R528H mutations. RESULTS: The acute loss of force for HypoPP muscle, triggered by a 2 mM Kchallenge, was prevented by low micromolar XEN1101, with an effective concentration of 0.30 μM for 50% protection. Application of 1 μM XEN1101, after the onset of 2 mM Kinduced weakness, restored the peak contractile force (70%-100% of baseline). DISCUSSION: The K7 potassium channel agonist XEN1101 is effective as both a prophylactic agent and as abortive therapy for management of low-Kinduced weakness in murine models of HypoPP. XEN1101 is more potent than the first-generation Kv7 agonist, retigabine, in our murine models of HypoPP and is also better tolerated in patients. These improvements provide a rationale for future clinical trials of XEN1101 in HypoPP patients.